Fandosentan (potassium)

Fandosentan potassium is a potent endothelin A receptor (ETAR) antagonist. Fandosentan potassium inhibits CYP2C9 and CYP3A4 activities with IC50 values of 39.6 and 21.6 μM, respectively. Fandosentan potassium reverses the hypoxic pulmonary vasoconstriction in the perinatal lamb. Fandosentan potassium can be used for pulmonary hypertension research[1][2].

Product Specifications

CAS Number

[221246-12-4]

UNSPSC

12352005

Target

Cytochrome P450; Endothelin Receptor

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Field of Research

Cardiovascular Disease

Smiles

O=C(C(N1C2=C(C=CC=C2)C(F)(F)F)=C(C3=CC4=C(OCO4)C(CC)=C3)C5=CC=CC=C5S1(=O)=O)O[K]

Molecular Formula

C25H17F3KNO6S

Molecular Weight

555.56

References & Citations

[1]Sahi J, et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact. 2006 Feb 1;159 (2) :156-68.|[2]Coe Y, et al. The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther. 2002 Aug;302 (2) :672-80.